7.97
-0.01 (-0.13%)
| Penutupan Terdahulu | 7.98 |
| Buka | 7.96 |
| Jumlah Dagangan | 899,098 |
| Purata Dagangan (3B) | 1,460,521 |
| Modal Pasaran | 658,103,744 |
| Harga / Buku (P/B) | 1.08 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Feb 2026 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Replimune Group, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.30 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 19.00 (Wedbush, 138.39%) | Beli |
| Median | 16.50 (107.03%) | |
| Rendah | 14.00 (Piper Sandler, 75.66%) | Beli |
| Purata | 16.50 (107.03%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 6.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 05 Feb 2026 | 14.00 (75.66%) | Beli | 6.93 |
| Wedbush | 04 Feb 2026 | 19.00 (138.39%) | Beli | 7.00 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | - | 8.04 | -25,000 | -201,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -201,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 8.04 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | Pengarah | 18 Feb 2026 | Dibuang (-) | 25,000 | 8.04 | 201,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update |
| 18 Dec 2025 | Pengumuman | Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |